Cancer-fighting immune cells in patients with lung cancer whose tumors do not respond to immunotherapies appear to be running on a different "program" that makes them less effective than immune cells in patients whose cancers respond to these immune treatments, suggests a new study led by researchers at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy.
Combining a histone deacetylase inhibitor drug with immunotherapy agents is safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical trial led by researchers
E-Mail
IMAGE: The AstroPath platform allows for the assessment of the level of expression of a given marker on individual cells, while maintaining information on their spatial location. Shown here is. view more
Credit: Seyoun Park, Ph.D.
Pairing sky-mapping algorithms with advanced immunofluorescence imaging of cancer biopsies, researchers at The Mark Foundation Center for Advanced Genomics and Imaging at Johns Hopkins University and the Bloomberg~Kimmel Institute for Cancer Immunotherapy developed a robust platform to guide immunotherapy by predicting which cancers will respond to specific therapies targeting the immune system.
A new platform, called AstroPath, melds astronomic image analysis and mapping with pathology specimens to analyze microscopic images of tumors.
Molecular biologist Erika Pearce joins Johns Hopkins as Bloomberg Distinguished Professor
A leading expert in the field of immunometabolism, she comes to the university from the Max Planck Institute of Immunology and Epigenetics
Image caption: Erika Pearce By Saralyn Cruickshank / Published April 6, 2021
Molecular biologist Erika Pearce, whose groundbreaking research into the role of metabolism in immune system regulation has led to fundamental discoveries about cellular biology and new avenues for drug development, will join Johns Hopkins University as a Bloomberg Distinguished Professor.
An international leader in the field of immunometabolism, Pearce has always had a fascination with how the body works. As a child, she was drawn to human anatomy books, spending her time scouring the pages and dreaming of becoming a doctor. But a course on basic immunology during her undergraduate studies at Cornell University sparked a love of res
New software package employs deep-learning algorithms to analyze T-cell receptor sequencing data
Researchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center have developed DeepTCR, a software package that employs deep-learning algorithms to analyze T-cell receptor (TCR) sequencing data. T-cell receptors are found on the surface of immune T cells. These receptors bind to certain antigens, or proteins, found on abnormal cells, such as cancer cells and cells infected with a virus or bacteria, to guide the T cells to attack and destroy the affected cells. DeepTCR is an open-source software that can be used to answer questions in research into infectious disease, cancer immunology and autoimmune disease; any place where the immune system has a role through its T-cell receptors, said lead study author John-William Sidhom, an M.D./Ph.D. student at the Johns Hopkins University School of Medicine and Department of Biomedical Engineering